Herbal/Natural Product | Prescribed Medicine | Interaction Rating | Mechanism of Interaction |
---|---|---|---|
Aloe (12) | Insulin (1) | Moderate | Additive effects, lower blood glucose levels lead to increased risk of hypoglycaemia. |
Chamomile (29) | Diazepam (1) | Moderate | Additive effects of benzodiazepines, lead to increased risk of CNS depression, psychomotor impairment. |
Propranolol (1) | Moderate | Inhibition of CYP1A2 and CYP2D6 (in vitro and in vivo). Increase levels of drugs metabolized by this enzyme. | |
Diclofenac (1) | Moderate | Inhibition of CYP2C9 (in vitro). Increase levels of drugs metabolized by this enzyme. | |
Ondansetron (1) | Minor | Inhibition of CYP1A2 (in vitro and in vivo). Increase levels of drugs metabolized by this enzyme. | |
Chlorpromazine (1) | Moderate | Inhibition of CYP2D6 (in vitro). Increase levels of drugs metabolized by this enzyme. | |
Dyhidrocodeine (2) | Moderate | Additive effects of codeine, lead to increased risk of CNS depression, psychomotor impairment. | |
Co-codamol (1) | Moderate | Additive effects of codeine, lead to increased risk of CNS depression, psychomotor impairment. | |
Cranberry (42) | Diazepam (1) | Moderate | Inhibition of CYP2C9 (in vitro), contradictory results in clinical research. Increase levels of drugs metabolized by this enzyme. |
Diclofenac (1) | Moderate | Inhibition of CYP2C9 (in vitro), contradictory results in clinical research. Increase levels of drugs metabolized by this enzyme | |
Fish oil (24) | Progesterone pessaries (2) | Moderate | Progesterone may interfere with the triglyceride lowering effects of fish oils. |
Dalteparin (2) | Moderate | Additive effects, lead to increased risk of bleeding. | |
Enoxaparin (1) | Moderate | Additive effects, lead to increased risk of bleeding. | |
Labetolol (2) | Moderate | Additive effects with antihypertensive, lead to increased risk of hypotension. | |
Methyldopa (1) | Moderate | Additive effects with antihypertensive, lead to increases risk of hypotension. | |
Ginger (50) | Metformin (1) | Moderate | Additive effects, might increase insulin level and/or decrease blood glucose levels, may lead to hypoglycemia. |
Insulin (2) | Moderate | Additive effects, might increase insulin level and/or decrease blood glucose levels, may lead to hypoglycemia. | |
Aspirin (4) | Moderate | Inhibit thromboxane synthetase and decrease platelet aggregation lead to increased risk of bleeding. | |
Nifedipine (1) | Major | Significantly inhibits platelet aggregation, synergetic effects, may lead to potential cardiovascular and cerebrovascular complications. | |
Ginseng (4) | Metformin (1) | Moderate | Additive effects, might increase insulin level and/or decrease blood glucose levels, may lead to hypoglycemia. |
Diazepam (1) | Moderate | Additive effects of benzodiazepines, lead to increased risk of CNS depression, psychomotor impairment | |
Grapefruit (8) | Itraconazole (1) | Moderate | Might affect absorption and might increase or decrease itraconazole levels. |
Propranolol (1) | Moderate | Inhibition of CYP1A2 (preliminary evidence). Increase levels of drugs metabolized by this enzyme. | |
Diclofenac (1) | Moderate | Inhibition of CYP2C9 (preliminary evidence), contradictory results in clinical research. Increase levels of drugs metabolized by this enzyme. | |
Omeprazole (1) | Moderate | Inhibition of CYP2C19 (preliminary evidence), contradictory results in clinical research. Increase levels of drugs metabolized by this enzyme. | |
Sage (1) | Co-codamol (1) | Moderate | Inhibition of CYP2D6 (in vitro). Increase levels of drugs metabolized by this enzyme. |